Industry Research Reports

Home > Reports > Medical Care > Male Hypogonadism - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Male Hypogonadism - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 111 Pages

Report ld: 2336827

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Male hypogonadism is a condition in which the body doesn't produce enough of the hormone that plays a key role in masculine growth and development during puberty (testosterone) or enough sperm or both. You can be born with male hypogonadism, or it can develop later in life, often from injury or infection.

The global market for Male Hypogonadism was estimated to be worth US$ 3040.6 million in 2023 and is forecast to a readjusted size of US$ 3721.7 million by 2030 with a CAGR of 2.5% during the forecast period 2024-2030

Male Hypogonadism Market Size

M= millions and B=billions

North American market for Male Hypogonadism was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Male Hypogonadism was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Male Hypogonadism was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Male Hypogonadism include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd. and Finox Biotech, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Male Hypogonadism, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Male Hypogonadism by region & country, by Type, and by Application.

The Male Hypogonadism market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Male Hypogonadism.

Market Segmentation

Report Metric
Details
Report Title
Male Hypogonadism - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 3721.7 million
CAGR(2024-2030)
2.5%
Market Size Available for Years
2019-2030
Global Male Hypogonadism Companies Covered
Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd., Finox Biotech, Teva Pharmaceutical Industries Ltd., Bayer AG, IBSA Institut Biochimque
Global Male Hypogonadism Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Male Hypogonadism Market, Segment by Type
Testosterone Replacement Therapy

Gonadotropin-Releasing Hormones Therapy
Global Male Hypogonadism Market, Segment by Application
Kallmann Syndrome

Klinefelters Syndrome

Pituitary Disorders

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Male Hypogonadism manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Male Hypogonadism in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Male Hypogonadism in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Male Hypogonadism Product Introduction
    1.2 Global Male Hypogonadism Market Size Forecast
    1.3 Male Hypogonadism Market Trends & Drivers
        1.3.1 Male Hypogonadism Industry Trends
        1.3.2 Male Hypogonadism Market Drivers & Opportunity
        1.3.3 Male Hypogonadism Market Challenges
        1.3.4 Male Hypogonadism Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Male Hypogonadism Players Revenue Ranking (2023)
    2.2 Global Male Hypogonadism Revenue by Company (2019-2024)
    2.3 Key Companies Male Hypogonadism Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Male Hypogonadism Product Offered
    2.5 Key Companies Time to Begin Mass Production of Male Hypogonadism
    2.6 Male Hypogonadism Market Competitive Analysis
        2.6.1 Male Hypogonadism Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Male Hypogonadism Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Male Hypogonadism as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Testosterone Replacement Therapy
        3.1.2 Gonadotropin-Releasing Hormones Therapy
    3.2 Global Male Hypogonadism Sales Value by Type
        3.2.1 Global Male Hypogonadism Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Male Hypogonadism Sales Value, by Type (2019-2030)
        3.2.3 Global Male Hypogonadism Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Kallmann Syndrome
        4.1.2 Klinefelters Syndrome
        4.1.3 Pituitary Disorders
        4.1.4 Others
    4.2 Global Male Hypogonadism Sales Value by Application
        4.2.1 Global Male Hypogonadism Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Male Hypogonadism Sales Value, by Application (2019-2030)
        4.2.3 Global Male Hypogonadism Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Male Hypogonadism Sales Value by Region
        5.1.1 Global Male Hypogonadism Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Male Hypogonadism Sales Value by Region (2019-2024)
        5.1.3 Global Male Hypogonadism Sales Value by Region (2025-2030)
        5.1.4 Global Male Hypogonadism Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Male Hypogonadism Sales Value, 2019-2030
        5.2.2 North America Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Male Hypogonadism Sales Value, 2019-2030
        5.3.2 Europe Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Male Hypogonadism Sales Value, 2019-2030
        5.4.2 Asia Pacific Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Male Hypogonadism Sales Value, 2019-2030
        5.5.2 South America Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Male Hypogonadism Sales Value, 2019-2030
        5.6.2 Middle East & Africa Male Hypogonadism Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Male Hypogonadism Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Male Hypogonadism Sales Value
    6.3 United States
        6.3.1 United States Male Hypogonadism Sales Value, 2019-2030
        6.3.2 United States Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Male Hypogonadism Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Male Hypogonadism Sales Value, 2019-2030
        6.4.2 Europe Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Male Hypogonadism Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Male Hypogonadism Sales Value, 2019-2030
        6.5.2 China Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Male Hypogonadism Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Male Hypogonadism Sales Value, 2019-2030
        6.6.2 Japan Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Male Hypogonadism Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Male Hypogonadism Sales Value, 2019-2030
        6.7.2 South Korea Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Male Hypogonadism Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Male Hypogonadism Sales Value, 2019-2030
        6.8.2 Southeast Asia Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Male Hypogonadism Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Male Hypogonadism Sales Value, 2019-2030
        6.9.2 India Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Male Hypogonadism Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Astrazeneca Plc.
        7.1.1 Astrazeneca Plc. Profile
        7.1.2 Astrazeneca Plc. Main Business
        7.1.3 Astrazeneca Plc. Male Hypogonadism Products, Services and Solutions
        7.1.4 Astrazeneca Plc. Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.1.5 Astrazeneca Plc. Recent Developments
    7.2 Merck & Co. Inc.
        7.2.1 Merck & Co. Inc. Profile
        7.2.2 Merck & Co. Inc. Main Business
        7.2.3 Merck & Co. Inc. Male Hypogonadism Products, Services and Solutions
        7.2.4 Merck & Co. Inc. Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.2.5 Merck & Co. Inc. Recent Developments
    7.3 Laboratories Genevrier
        7.3.1 Laboratories Genevrier Profile
        7.3.2 Laboratories Genevrier Main Business
        7.3.3 Laboratories Genevrier Male Hypogonadism Products, Services and Solutions
        7.3.4 Laboratories Genevrier Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.3.5 Allergan Plc. Recent Developments
    7.4 Allergan Plc.
        7.4.1 Allergan Plc. Profile
        7.4.2 Allergan Plc. Main Business
        7.4.3 Allergan Plc. Male Hypogonadism Products, Services and Solutions
        7.4.4 Allergan Plc. Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.4.5 Allergan Plc. Recent Developments
    7.5 Endo International Plc.
        7.5.1 Endo International Plc. Profile
        7.5.2 Endo International Plc. Main Business
        7.5.3 Endo International Plc. Male Hypogonadism Products, Services and Solutions
        7.5.4 Endo International Plc. Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.5.5 Endo International Plc. Recent Developments
    7.6 Ferring
        7.6.1 Ferring Profile
        7.6.2 Ferring Main Business
        7.6.3 Ferring Male Hypogonadism Products, Services and Solutions
        7.6.4 Ferring Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.6.5 Ferring Recent Developments
    7.7 AbbVie Inc.
        7.7.1 AbbVie Inc. Profile
        7.7.2 AbbVie Inc. Main Business
        7.7.3 AbbVie Inc. Male Hypogonadism Products, Services and Solutions
        7.7.4 AbbVie Inc. Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.7.5 AbbVie Inc. Recent Developments
    7.8 Eli Lilly and Company Ltd.
        7.8.1 Eli Lilly and Company Ltd. Profile
        7.8.2 Eli Lilly and Company Ltd. Main Business
        7.8.3 Eli Lilly and Company Ltd. Male Hypogonadism Products, Services and Solutions
        7.8.4 Eli Lilly and Company Ltd. Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.8.5 Eli Lilly and Company Ltd. Recent Developments
    7.9 Finox Biotech
        7.9.1 Finox Biotech Profile
        7.9.2 Finox Biotech Main Business
        7.9.3 Finox Biotech Male Hypogonadism Products, Services and Solutions
        7.9.4 Finox Biotech Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.9.5 Finox Biotech Recent Developments
    7.10 Teva Pharmaceutical Industries Ltd.
        7.10.1 Teva Pharmaceutical Industries Ltd. Profile
        7.10.2 Teva Pharmaceutical Industries Ltd. Main Business
        7.10.3 Teva Pharmaceutical Industries Ltd. Male Hypogonadism Products, Services and Solutions
        7.10.4 Teva Pharmaceutical Industries Ltd. Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
    7.11 Bayer AG
        7.11.1 Bayer AG Profile
        7.11.2 Bayer AG Main Business
        7.11.3 Bayer AG Male Hypogonadism Products, Services and Solutions
        7.11.4 Bayer AG Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.11.5 Bayer AG Recent Developments
    7.12 IBSA Institut Biochimque
        7.12.1 IBSA Institut Biochimque Profile
        7.12.2 IBSA Institut Biochimque Main Business
        7.12.3 IBSA Institut Biochimque Male Hypogonadism Products, Services and Solutions
        7.12.4 IBSA Institut Biochimque Male Hypogonadism Revenue (US$ Million) & (2019-2024)
        7.12.5 IBSA Institut Biochimque Recent Developments

 8 Industry Chain Analysis
    8.1 Male Hypogonadism Industrial Chain
    8.2 Male Hypogonadism Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Male Hypogonadism Sales Model
        8.5.2 Sales Channel
        8.5.3 Male Hypogonadism Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Male Hypogonadism Market Trends
    Table 2. Male Hypogonadism Market Drivers & Opportunity
    Table 3. Male Hypogonadism Market Challenges
    Table 4. Male Hypogonadism Market Restraints
    Table 5. Global Male Hypogonadism Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Male Hypogonadism Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Male Hypogonadism Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Male Hypogonadism Product Type
    Table 9. Key Companies Time to Begin Mass Production of Male Hypogonadism
    Table 10. Global Male Hypogonadism Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Male Hypogonadism as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Male Hypogonadism Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Male Hypogonadism Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Male Hypogonadism Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Male Hypogonadism Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Male Hypogonadism Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Male Hypogonadism Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Male Hypogonadism Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Male Hypogonadism Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Male Hypogonadism Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Male Hypogonadism Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Male Hypogonadism Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Male Hypogonadism Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Male Hypogonadism Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Male Hypogonadism Sales Value by Region (2019-2024) & (%)
    Table 27. Global Male Hypogonadism Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Male Hypogonadism Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Male Hypogonadism Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Male Hypogonadism Sales Value, (2025-2030) & (US$ Million)
    Table 31. Astrazeneca Plc. Basic Information List
    Table 32. Astrazeneca Plc. Description and Business Overview
    Table 33. Astrazeneca Plc. Male Hypogonadism Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Male Hypogonadism Business of Astrazeneca Plc. (2019-2024)
    Table 35. Astrazeneca Plc. Recent Developments
    Table 36. Merck & Co. Inc. Basic Information List
    Table 37. Merck & Co. Inc. Description and Business Overview
    Table 38. Merck & Co. Inc. Male Hypogonadism Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Male Hypogonadism Business of Merck & Co. Inc. (2019-2024)
    Table 40. Merck & Co. Inc. Recent Developments
    Table 41. Laboratories Genevrier Basic Information List
    Table 42. Laboratories Genevrier Description and Business Overview
    Table 43. Laboratories Genevrier Male Hypogonadism Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Male Hypogonadism Business of Laboratories Genevrier (2019-2024)
    Table 45. Laboratories Genevrier Recent Developments
    Table 46. Allergan Plc. Basic Information List
    Table 47. Allergan Plc. Description and Business Overview
    Table 48. Allergan Plc. Male Hypogonadism Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Male Hypogonadism Business of Allergan Plc. (2019-2024)
    Table 50. Allergan Plc. Recent Developments
    Table 51. Endo International Plc. Basic Information List
    Table 52. Endo International Plc. Description and Business Overview
    Table 53. Endo International Plc. Male Hypogonadism Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Male Hypogonadism Business of Endo International Plc. (2019-2024)
    Table 55. Endo International Plc. Recent Developments
    Table 56. Ferring Basic Information List
    Table 57. Ferring Description and Business Overview
    Table 58. Ferring Male Hypogonadism Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Male Hypogonadism Business of Ferring (2019-2024)
    Table 60. Ferring Recent Developments
    Table 61. AbbVie Inc. Basic Information List
    Table 62. AbbVie Inc. Description and Business Overview
    Table 63. AbbVie Inc. Male Hypogonadism Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Male Hypogonadism Business of AbbVie Inc. (2019-2024)
    Table 65. AbbVie Inc. Recent Developments
    Table 66. Eli Lilly and Company Ltd. Basic Information List
    Table 67. Eli Lilly and Company Ltd. Description and Business Overview
    Table 68. Eli Lilly and Company Ltd. Male Hypogonadism Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Male Hypogonadism Business of Eli Lilly and Company Ltd. (2019-2024)
    Table 70. Eli Lilly and Company Ltd. Recent Developments
    Table 71. Finox Biotech Basic Information List
    Table 72. Finox Biotech Description and Business Overview
    Table 73. Finox Biotech Male Hypogonadism Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Male Hypogonadism Business of Finox Biotech (2019-2024)
    Table 75. Finox Biotech Recent Developments
    Table 76. Teva Pharmaceutical Industries Ltd. Basic Information List
    Table 77. Teva Pharmaceutical Industries Ltd. Description and Business Overview
    Table 78. Teva Pharmaceutical Industries Ltd. Male Hypogonadism Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Male Hypogonadism Business of Teva Pharmaceutical Industries Ltd. (2019-2024)
    Table 80. Teva Pharmaceutical Industries Ltd. Recent Developments
    Table 81. Bayer AG Basic Information List
    Table 82. Bayer AG Description and Business Overview
    Table 83. Bayer AG Male Hypogonadism Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Male Hypogonadism Business of Bayer AG (2019-2024)
    Table 85. Bayer AG Recent Developments
    Table 86. IBSA Institut Biochimque Basic Information List
    Table 87. IBSA Institut Biochimque Description and Business Overview
    Table 88. IBSA Institut Biochimque Male Hypogonadism Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Male Hypogonadism Business of IBSA Institut Biochimque (2019-2024)
    Table 90. IBSA Institut Biochimque Recent Developments
    Table 91. Key Raw Materials Lists
    Table 92. Raw Materials Key Suppliers Lists
    Table 93. Male Hypogonadism Downstream Customers
    Table 94. Male Hypogonadism Distributors List
    Table 95. Research Programs/Design for This Report
    Table 96. Key Data Information from Secondary Sources
    Table 97. Key Data Information from Primary Sources
    Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Male Hypogonadism Product Picture
    Figure 2. Global Male Hypogonadism Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Male Hypogonadism Sales Value (2019-2030) & (US$ Million)
    Figure 4. Male Hypogonadism Report Years Considered
    Figure 5. Global Male Hypogonadism Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Male Hypogonadism Revenue in 2023
    Figure 7. Male Hypogonadism Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Testosterone Replacement Therapy Picture
    Figure 9. Gonadotropin-Releasing Hormones Therapy Picture
    Figure 10. Global Male Hypogonadism Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Male Hypogonadism Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Kallmann Syndrome
    Figure 13. Product Picture of Klinefelters Syndrome
    Figure 14. Product Picture of Pituitary Disorders
    Figure 15. Product Picture of Others
    Figure 16. Global Male Hypogonadism Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 17. Global Male Hypogonadism Sales Value Market Share by Application, 2023 & 2030
    Figure 18. North America Male Hypogonadism Sales Value (2019-2030) & (US$ Million)
    Figure 19. North America Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    Figure 20. Europe Male Hypogonadism Sales Value (2019-2030) & (US$ Million)
    Figure 21. Europe Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    Figure 22. Asia Pacific Male Hypogonadism Sales Value (2019-2030) & (US$ Million)
    Figure 23. Asia Pacific Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    Figure 24. South America Male Hypogonadism Sales Value (2019-2030) & (US$ Million)
    Figure 25. South America Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    Figure 26. Middle East & Africa Male Hypogonadism Sales Value (2019-2030) & (US$ Million)
    Figure 27. Middle East & Africa Male Hypogonadism Sales Value by Country (%), 2023 VS 2030
    Figure 28. Key Countries/Regions Male Hypogonadism Sales Value (%), (2019-2030)
    Figure 29. United States Male Hypogonadism Sales Value, (2019-2030) & (US$ Million)
    Figure 30. United States Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
    Figure 31. United States Male Hypogonadism Sales Value by Application (%), 2023 VS 2030
    Figure 32. Europe Male Hypogonadism Sales Value, (2019-2030) & (US$ Million)
    Figure 33. Europe Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
    Figure 34. Europe Male Hypogonadism Sales Value by Application (%), 2023 VS 2030
    Figure 35. China Male Hypogonadism Sales Value, (2019-2030) & (US$ Million)
    Figure 36. China Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
    Figure 37. China Male Hypogonadism Sales Value by Application (%), 2023 VS 2030
    Figure 38. Japan Male Hypogonadism Sales Value, (2019-2030) & (US$ Million)
    Figure 39. Japan Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
    Figure 40. Japan Male Hypogonadism Sales Value by Application (%), 2023 VS 2030
    Figure 41. South Korea Male Hypogonadism Sales Value, (2019-2030) & (US$ Million)
    Figure 42. South Korea Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
    Figure 43. South Korea Male Hypogonadism Sales Value by Application (%), 2023 VS 2030
    Figure 44. Southeast Asia Male Hypogonadism Sales Value, (2019-2030) & (US$ Million)
    Figure 45. Southeast Asia Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
    Figure 46. Southeast Asia Male Hypogonadism Sales Value by Application (%), 2023 VS 2030
    Figure 47. India Male Hypogonadism Sales Value, (2019-2030) & (US$ Million)
    Figure 48. India Male Hypogonadism Sales Value by Type (%), 2023 VS 2030
    Figure 49. India Male Hypogonadism Sales Value by Application (%), 2023 VS 2030
    Figure 50. Male Hypogonadism Industrial Chain
    Figure 51. Male Hypogonadism Manufacturing Cost Structure
    Figure 52. Channels of Distribution (Direct Sales, and Distribution)
    Figure 53. Bottom-up and Top-down Approaches for This Report
    Figure 54. Data Triangulation

Description

Male hypogonadism is a condition in which the body doesn't produce enough of the hormone that plays a key role in masculine growth and development during puberty (testosterone) or enough sperm or both. You can be born with male hypogonadism, or it can develop later in life, often from injury or infection.

The global market for Male Hypogonadism was estimated to be worth US$ 3040.6 million in 2023 and is forecast to a readjusted size of US$ 3721.7 million by 2030 with a CAGR of 2.5% during the forecast period 2024-2030

North American market for Male Hypogonadism was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Male Hypogonadism was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Male Hypogonadism was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Market Segmentation